Virpax Pharmaceuticals (VRPX) Competitors $0.33 +0.01 (+4.30%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VRPX vs. GLTO, TRIB, MBRX, ABVC, VINC, EDSA, AIMD, ONVO, SYRS, and GTBPShould you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Galecto (GLTO), Trinity Biotech (TRIB), Moleculin Biotech (MBRX), ABVC BioPharma (ABVC), Vincerx Pharma (VINC), Edesa Biotech (EDSA), Ainos (AIMD), Organovo (ONVO), Syros Pharmaceuticals (SYRS), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical products" industry. Virpax Pharmaceuticals vs. Galecto Trinity Biotech Moleculin Biotech ABVC BioPharma Vincerx Pharma Edesa Biotech Ainos Organovo Syros Pharmaceuticals GT Biopharma Virpax Pharmaceuticals (NASDAQ:VRPX) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Do analysts recommend VRPX or GLTO? Virpax Pharmaceuticals currently has a consensus price target of $3.00, indicating a potential upside of 809.09%. Galecto has a consensus price target of $10.00, indicating a potential upside of 112.77%. Given Virpax Pharmaceuticals' higher probable upside, analysts plainly believe Virpax Pharmaceuticals is more favorable than Galecto.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is VRPX or GLTO more profitable? Galecto's return on equity of -76.96% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Virpax PharmaceuticalsN/A -1,554.34% -338.29% Galecto N/A -76.96%-66.59% Which has preferable earnings and valuation, VRPX or GLTO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/AGalectoN/AN/A-$38.35M-$19.14-0.25 Which has more volatility & risk, VRPX or GLTO? Virpax Pharmaceuticals has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Galecto has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Does the media refer more to VRPX or GLTO? In the previous week, Virpax Pharmaceuticals had 2 more articles in the media than Galecto. MarketBeat recorded 2 mentions for Virpax Pharmaceuticals and 0 mentions for Galecto. Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Galecto'saverage media sentiment score. Company Overall Sentiment Virpax Pharmaceuticals Neutral Galecto Neutral Do institutionals & insiders believe in VRPX or GLTO? 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.2% of Galecto shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 11.9% of Galecto shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community prefer VRPX or GLTO? Galecto received 29 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. Likewise, 60.38% of users gave Galecto an outperform vote while only 60.00% of users gave Virpax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVirpax PharmaceuticalsOutperform Votes360.00% Underperform Votes240.00% GalectoOutperform Votes3260.38% Underperform Votes2139.62% SummaryGalecto beats Virpax Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRPX vs. The Competition Export to ExcelMetricVirpax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.61M$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E RatioN/A10.5089.8217.18Price / SalesN/A195.801,116.21116.95Price / CashN/A57.1642.8937.86Price / Book0.205.094.784.78Net Income-$15.19M$151.83M$120.23M$225.60M7 Day Performance-17.50%-2.13%-1.92%-1.23%1 Month Performance-45.00%-3.10%11.49%3.36%1 Year Performance-90.83%11.54%30.57%16.60% Virpax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRPXVirpax Pharmaceuticals1.0729 of 5 stars$0.33+4.3%$3.00+809.1%-90.8%$1.61MN/A0.007GLTOGalecto2.1615 of 5 stars$5.15+1.4%$10.00+94.2%-70.2%$6.78MN/A-0.2740TRIBTrinity Biotech1.2132 of 5 stars$0.89-1.7%N/A-64.5%$6.78M$56.83M-0.39480News CoveragePositive NewsGap DownMBRXMoleculin Biotech2.3585 of 5 stars$2.18-6.0%$24.00+1,000.9%-83.4%$6.54MN/A0.0020News CoverageABVCABVC BioPharma0.9744 of 5 stars$0.50-1.8%N/A-52.4%$6.43M$509,788.00-0.5830News CoverageVINCVincerx Pharma2.2589 of 5 stars$0.19-1.2%$2.00+959.9%-75.1%$6.35MN/A-0.1960Gap UpEDSAEdesa Biotech3.554 of 5 stars$1.93-0.3%$21.00+988.1%-64.1%$6.27MN/A-1.0020Earnings ReportPositive NewsGap DownAIMDAinosN/A$0.45+1.1%N/A-80.1%$6.16M$120,000.000.0046Gap DownONVOOrganovoN/A$0.39-3.4%N/A-67.6%$6.01M$110,000.000.0020Analyst ForecastSYRSSyros Pharmaceuticals4.2461 of 5 stars$0.22+4.4%$3.33+1,441.1%-96.5%$5.80M$9.94M-0.07120Gap UpGTBPGT Biopharma3.6558 of 5 stars$2.59-5.8%$11.00+324.7%-78.3%$5.79MN/A0.008Positive NewsGap Up Related Companies and Tools Related Companies GLTO Alternatives TRIB Alternatives MBRX Alternatives ABVC Alternatives VINC Alternatives EDSA Alternatives AIMD Alternatives ONVO Alternatives SYRS Alternatives GTBP Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRPX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
